8 Amendments of Martin HÄUSLING related to 2018/2775(RSP)
Amendment 8 #
Recital C
C. whereas Cannabis productproducts derived from Cannabis that are used for medicinal purposes are broadly referred to as “medical cannabis”;
Amendment 14 #
Recital F
Amendment 21 #
Recital K
K. whereas there is limited evidenceare indications that cannabis or cannabinoids are effective for increasing appetite and decreasing weight loss associated with HIV/AIDS, improving clinician-measured multiple sclerosis spasticity symptoms, improving symptoms of Tourette syndrome, improving symptoms ofsymptoms of mental disorders (e.g. psychosis, depression, posttraumatic stress disorder, Tourette syndrome);
Amendment 41 #
Paragraph 1
1. Stresses the need for the Commission and national authorities to draw a clear distinctionistinguish between medical cannabis and other applicrecreations ofal cannabis;
Amendment 44 #
Paragraph 2
2. Considers that research on medical cannabis1a has been underfunded and should be properly addressed under the next Framework Programme 9; and national research programmes; _________________ 1aAlso research on recreational cannabis can be supportive for medical cannabis
Amendment 49 #
Paragraph 3
3. Calls on the Commission and Member States to address the regulatory and financial barriers which weigh on scientific research in the use of cannabis for medicinal purposes;2a; _________________ 2aResearch on Cannabis in general is needed; lessons can also be drawn for medical cannabis from research on recreational cannabis
Amendment 50 #
Paragraph 4
4. Calls on the Commission to determine the priority areas for research on cannabis for medicinal and recreational3a purposes in agreement with competent authorities and drawing on pioneering research in other countries and focusing in those areas which may have the greatest added-value; _________________ 3aResearch in the field of recreational cannabis can also be useful for the use and applications of medical cannabis
Amendment 54 #
Paragraph 5
5. Calls on the Commission to develop a comprehensive strategy to ensure the highest standards for the research, development, authorisation, marketing, pharmacovigilance and avoidance of abuse for cannabis-based medicines; emphasises the need for standardisation and unification of products containing Cannabis-based medicines;